Breast Cancer

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Denosumab-desu (Osvyrti and Jubereq) received FDA approval in the same indications as reference denosumab (Prolia and Xgeva).

The phase 3 lidERA trial shows improved iDFS with giredestrant vs standard therapy in early ER-positive, HER2-negative breast cancer.

Gedatolisib’s NDA filing to the FDA is supported by VIKTORIA-1 data showing marked PFS improvements in HR+/HER2– advanced breast cancer.

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

Eddy Saad, MD, discusses how AI-generated synthetic cohorts derived from real-world data may accelerate trial design and collaboration in metastatic breast cancer.

The FDA has approved pertuzumab-dpzb as the first interchangeable biosimilar for pertuzumab across several indications in HER2-positive breast cancer.

Arya Roy, MBBS, discusses breakthroughs and adverse effects associated with antibody-drug conjugates in breast cancer.

Erika P. Hamilton, MD, discusses initial efficacy and safety data with the TROP2-targeted ADC DB-1305/BNT325 in pretreated metastatic TNBC.

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

Erica L. Mayer, MD, MPH, discusses data with giredestrant and how the evERA trial shows the potential for SERD-based regimens in ER-positive breast cancer.

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

The phase 3 ASCENT-07 trial did not meet its primary PFS end point with first-line sacituzumab govitecan in hormone receptor–positive, HER2-negative breast cancer.

Ivonescimab plus chemotherapy has received breakthrough therapy designation as first-line therapy in patients with triple-negative breast cancer.

Yuan Yuan, MD, PhD, discusses the use of sacituzumab govitecan in TNBC and remaining questions about the use of CDK4/6 inhibitors in ER-positive disease.

Sara A. Hurvitz, MD, FACP, unpacks data with adjuvant ribociclib plus endocrine therapy from the 5-year prespecified analysis of the NATALEE trial.

Mayo Clinic discovery of breast cancer treatment resistance can lead to new hope for some patients.

Sara A. Hurvitz, MD, FACP, shares efficacy and safety data from the VIKTORIA-1 study in endocrine-resistant HR-positive breast cancer.

Sara A. Hurvitz, MD, FACP, explains the clinical rationale for targeting the PI3K/mTOR pathways with gedatolisib in the VIKTORIA-1 trial.

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.

Sara A. Hurvitz, MD, FACP, discusses the design of VIKTORIA-1, key efficacy and safety findings, and how these data may influence breast cancer management.

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.